Skip to content

Human Composite Facial Allotransplantation

Human Composite Facial Allotransplantation

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05117190
Enrollment
3
Registered
2021-11-11
Start date
2014-10-21
Completion date
2021-03-18
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transplantation: Facial Transplantation

Keywords

Facial Transplantation

Brief summary

Allotransplantation of maxillofacial of subject with severe facial deformities due to traumatic events.

Detailed description

A facial transplantation is a highly dynamic, prolonged operation requiring teams communicating seamlessly through its duration. This is similar to complex solid organ transplant teams at Methodist Transplant Institute. The Institute's clinical experience in management of complex facial defects and deformities along with the personnel and infrastructure at Methodist Dallas transplant institute would help develop a center for Facial Allotransplantation. The team experience, true collaboration, creativity and a unique approach to each patient would help provide the optimal care and reconstruction for the face allotransplant patient both before and after surgery. The purpose of this study is centered on the advancement of a safe and effective procedure for Facial Allotransplantation at Methodist Hospital Medical Center at Dallas. Composite tissue allotransplantation for facial reconstruction is in its infancy as liver transplantation was 30 years ago when the first liver transplant was completed in Texas. This study will establish Methodist Hospital System as a center for Facial Allotransplantation for reconstruction of extensive facial defects resulting in functional loss and poor quality of life. Patient participation post transplantation will either be for life, or failure of the composite tissue allograft. Patient enrollment will be initiated immediately after the IRB approval. The enrollment period will be completed after the patient receives the final transplant, and the study will be completed at 24 months after the final transplant. However, all patients enrolled into the study will have lifelong follow up with immunosuppressive management, psychological support, and evaluation of functional recovery per protocol.

Interventions

PROCEDUREFacial Allotransplantation

Sponsors

Methodist Health System
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Between ages 18-70 years * Must be willing to undergo major facial reconstruction * Be able to understand the pre and post-transplantation evaluation, physical therapy, and follow up procedures * Conventional reconstruction deemed unsatisfactory

Exclusion criteria

* Medically unable to provide consent * Active infections such as Human Immunodeficiency Virus, mycobacteria, hepatitis B, and hepatitis C * Recent history of alcohol or IV drug or chemical dependency * Psychiatric evaluation that indicate mental instability or non-compliance * Cognitively impaired and Terminally ill * Women of child bearing age with intent to conceive, pregnant or lactating * Unable to receive immunosuppression after transplantation because of either geographic or financial limitations * End stage organ disease (renal failure, Congestive Heart Failure (CHF), Chronic Obstructive Pulmonary Disease (COPD), etc.) * Chronic infections such as osteomyelitis

Design outcomes

Primary

MeasureTime frameDescription
Modified Facial Clinimetric Evaluation Scalemeasured at 6 weeksvalidated quality-of-life instrument that is used to assess facial impairment and disability after facial paralysis.
Facial Disability Indexmeasured at 6 weeksa disease-specific, self-report instrument for the assessment of disabilities of patients with facial nerve disorders
SF-36 Health Surveymeasured at 6 weeksa set of generic, coherent, and easily administered quality-of-life measures

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORLikith V. Reddy, MD

Methodist Health System

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026